April 22 (Reuters) - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.
Under the deal, Abbott transferred generic and specialty drugs it had sold in Europe, Japan, Canada, Australia and New Zealand to a new publicly traded company in the Netherlands that also included Mylan's existing businesses.
03:27 Ahead of NAFTA talks, U.S. sets 20 percent duties on Canadian softwood lumber20
23:59 Shares in Takata suspended after reported bankruptcy filing plan16
01:48 Trump to propose large increase in deductions Americans can claim on their taxes18
19:18 U.S. Says Canada Lumber Duty Is Part of Trade Enforcer Drive19